Modificación de actitudes ante el Sida en estudiantes de enfermería: Resultados de una experiencia pedagógica

DOI: 10.4321/S1575-18132006000200007
  • [Show abstract] [Hide abstract]
    ABSTRACT: More than 20 years have passed since the human immunodeficiency virus (HIV)-1 was identified as the cause of AIDS (acquired immune deficiency syndrome). With rapid early progress, the development of a vaccine was predicted within 2-10 years. However, over two decades later, we have seen only a single vaccine candidate complete Phase III clinical efficacy trials. These trials showed the vaccine was not able to protect the trial volunteers from HIV infection or subsequently modify the early clinical progression. It is now accepted that the initial optimism in the field was misguided, as the complexity of the problem stretched beyond the known horizons of vaccinology, immunology and retrovirology. In the intervening 20 years, unprecedented research efforts have pushed the cutting edge of these fields forward to such a degree that we are better able to put the problem of developing a vaccine for HIV-1 into context. Now it is time to examine the prospects for HIV-1 vaccines and ascertain whether real progress is being made.
    Expert Reviews in Molecular Medicine 03/2005; 7(2):1-21. · 5.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The AIDS epidemic continues to spread throughout nations of Africa and Asia and is by now threatening to undermine the already frail infrastructure of developing countries in Sub-Saharan Africa that are hit the hardest. The only option to stem this epidemic is through inexpensive and efficacious vaccines that prevent or at least blunt HIV-1 infections. Despite decades of pre-clinical and clinical research such vaccines remain elusive. Most anti-viral vaccines act by inducing protective levels of virus-neutralizing antibodies. The envelope protein of HIV-1, the sole target of neutralizing antibodies, is constantly changing due to mutations, B cell epitopes are masked by heavy glycosylation and the protein's structural unfolding upon binding to its CD4 receptor and chemokine co-receptors. Efforts to induce broadly cross-reactive virus-neutralizing antibodies able to induce sterilizing or near sterilizing immunity to HIV-1 have thus failed. Studies have indicated that cell-mediated immune responses and in particular CD8+ T cell responses to internal viral proteins may control HIV-1 infections without necessarily preventing them. Adenoviral vectors expressing antigens of HIV-1 are eminently suited to stimulate potent CD8+ T cell responses against transgene products, such as antigens of HIV-1. They performed well in pre-clinical studies in rodents and nonhuman primates and are currently in human clinical trials. This review summarizes the published literature on adenoviral vectors as vaccine carriers for HIV-1 and discusses advantages and disadvantages of this vaccine modality.
    Current Gene Therapy 05/2005; 5(2):203-12. · 4.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The importance of the role of an advanced practice nurse in infectious diseases has been heightened by the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic. The unique abilities that are part of the expanded role enable the advanced practice nurse to utilize tools learned as a nurse and combine them with advanced clinical skills to be a comprehensive care provider. The clinical management of the patient with HIV is complex and requires up-to-date knowledge regarding the constantly changing science of the virus.
    Critical care nursing quarterly 03/1999; 21(4):22-30.


Available from
May 20, 2014